| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Coherus BioSciences (NASDAQ:CHRS) will release its quarterly earnings report on Thursday, 2025-08-07. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Coherus BioSciences to report an earnings per share (EPS) of $-0.26.
Coherus BioSciences bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
During the last quarter, the company reported an EPS missed by $0.22, leading to a 19.11% drop in the share price on the subsequent day.
Here's a look at Coherus BioSciences's past performance and the resulting price change:
| Quarter | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.13 | -0.13 | -0.12 | -0.16 |
| EPS Actual | -0.35 | -0.28 | -0.01 | -0.14 |
| Price Change % | -19.0% | 1.0% | 13.0% | 11.0% |
Shares of Coherus BioSciences were trading at $0.9102 as of August 05. Over the last 52-week period, shares are down 29.02%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.
To track all earnings releases for Coherus BioSciences visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: CHRS
